Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
24/07/2024 | 13:00 | Business Wire | Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
13/06/2024 | 13:00 | Business Wire | Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
07/06/2024 | 22:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
06/06/2024 | 22:30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
14/05/2024 | 13:30 | Business Wire | Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
14/05/2024 | 12:42 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
07/05/2024 | 15:00 | Business Wire | Syros to Participate in Upcoming Investor Conferences | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
07/05/2024 | 13:00 | Business Wire | Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
09/04/2024 | 13:00 | Business Wire | Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
02/04/2024 | 22:30 | Business Wire | Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
27/03/2024 | 12:30 | Business Wire | Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
27/03/2024 | 11:57 | IH Market News | U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
25/03/2024 | 12:00 | Business Wire | Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
20/03/2024 | 12:00 | Business Wire | Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
27/02/2024 | 13:00 | Business Wire | Syros to Participate in TD Cowen 44th Annual Health Care Conference | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
15/02/2024 | 02:56 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
14/02/2024 | 02:22 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
08/01/2024 | 13:00 | Business Wire | Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
26/12/2023 | 23:19 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
19/12/2023 | 22:53 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
19/12/2023 | 13:27 | Business Wire | Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
12/12/2023 | 22:12 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
06/12/2023 | 13:00 | Business Wire | Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
14/11/2023 | 13:30 | Business Wire | Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
07/11/2023 | 13:30 | Business Wire | Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
20/10/2023 | 22:15 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
02/10/2023 | 14:45 | Business Wire | Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
08/08/2023 | 13:30 | Business Wire | Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
01/08/2023 | 13:30 | Business Wire | Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 | NASDAQ:SYRS | Syros Pharmaceuticals Inc |
08/06/2023 | 13:30 | Business Wire | Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference | NASDAQ:SYRS | Syros Pharmaceuticals Inc |